News
🇪🇺 EuropeLatest pharmaceutical news, drug approvals, and EMA regulatory updates
Latest News
Why Europe Must Boost Clinical Trials for Future Growth
Europe's pharmaceutical landscape is at a crossroads. Increasing clinical trials can drive innovation and investment in the region.
May 2026 Global Health & WASH Funding Opportunities
Explore the latest funding opportunities in Global Health & WASH for May 2026, highlighting 14 new clinical trial initiatives that could impact pharmaceutical investments.
FDA Advances Real-Time Clinical Trials Implementation
The FDA has made notable strides in implementing real-time clinical trials, a development that could reshape the pharmaceutical landscape. This article explores the implications for business development teams and investors.
US Raises Concerns Over EU Pharmaceutical Regulations
The US has raised significant concerns regarding new EU pharmaceutical regulations, prompting a critical analysis of market implications for stakeholders.
EMA and FDA Align on Good AI Practice in Drug Development
The EMA and FDA have announced a collaborative approach to good AI practices in drug development. This alignment marks a significant regulatory update for the industry.
SERD Therapy Shows Strong Anti-Proliferative Activity in ER+/HER2- Breast Cancer
Recent findings highlight SERD therapy's robust anti-proliferative activity in early ER+/HER2- breast cancer. This breakthrough could reshape treatment strategies and investment opportunities.
MaaT Pharma Q1 2026 Business Update and Financial Results
MaaT Pharma has released its business update and financial results for Q1 2026, highlighting key regulatory developments and market implications.
The Critical Medicines Act: Transforming Pharma Manufacturing in Europe
The Critical Medicines Act is set to revolutionize pharmaceutical manufacturing in Europe. This article analyzes its implications for business development teams, investors, and analysts.
ESMO Breast Cancer Congress 2026: Key Insights for Investors
The ESMO Breast Cancer Congress 2026 unveiled critical insights for stakeholders in oncology. This article highlights key takeaways and implications for pharma teams.
Ireland's Clinical Trials: A Comparative Analysis with EU Peers
Ireland's clinical trial activity is on the rise, yet it still lags behind its EU peers. This article examines the implications for pharmaceutical stakeholders.
CHMP Meeting Highlights: Drug Approvals from May 2026
The CHMP meeting from May 18-21, 2026, yielded significant drug approvals that could reshape market dynamics. This article explores the implications for pharmaceutical stakeholders.
EFPIA Warns of Widening Access Gap Under US Pricing Reforms
The EFPIA raises concerns about the widening access gap for clinical trials under new US pricing reforms. This could have significant implications for the pharmaceutical industry.
EU Lawmakers Reach Provisional Deal on Critical Medicines Act: Market Analysis
EU lawmakers have reached a provisional deal on the Critical Medicines Act, aiming to ensure the availability of critical medicines. This article analyzes the market implications for pharmaceutical stakeholders.
European Biotechs Innovate in Cell and Gene Therapy Manufacturing
European biotechs are at the forefront of developing next-generation manufacturing technologies for cell and gene therapies. This article explores the latest advancements and their implications for the pharmaceutical landscape.
MHRA Consultation on Rare Disease Therapy Draft Guidance
The MHRA has launched a consultation for its draft guidance on rare disease therapies, a move that could reshape clinical trials and investment strategies in the sector.
First GLP-1 Gene Therapy Clinical Trial Approved in Europe
The European Medicines Agency has approved the first clinical trial for a GLP-1 gene therapy, marking a significant milestone in pharmaceutical innovation. This development has important implications for investors and pharma teams alike.
February Batch of Novel Medicines Recommended for Approval by EMA/CHMP
The EMA and CHMP have recommended a new batch of novel medicines for approval this February, marking significant advancements in the pharmaceutical landscape. This article explores the implications for business development teams, investors, and analysts.
ISCT 2026 Annual: Key Highlights and Insights
The ISCT 2026 Annual event in Dublin showcased groundbreaking advancements in cell and gene therapies. Key industry players shared insights that could shape the future of biopharma.
Global Pharmacovigilance Reporting: A Comparative Analysis
This article provides a comparative analysis of global pharmacovigilance reporting obligations across five major regulatory authorities, highlighting implications for the pharmaceutical industry.
CMA Deal Strengthens EU Medicine Supply Chains
The CMA deal marks a significant advancement in EU medicine supply chains, promising enhanced stability and efficiency. This article analyzes its implications for the pharmaceutical sector.